Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: out_of_the_loop who wrote (3764)	9/19/1999 10:42:00 PM
From: Hank	Read Replies (2) \| Respond to of 10293

First of all, it's obvious that you do not have any experience in research or clinical development. If you did, you would not assume that a test population of 200 patients is clinically significant given the fact that millions of people suffer from colds each year and that these colds can potentially be caused by 200 different viral types. Second, whether or not a virus gets to attach to I-CAM or any other receptor in the presence of an inhibitor DOES depend on the relative affinity of both the virus and the inhibitor. Unless zinc binds I-CAM irreversibly, which it does not, there is an on-off rate for it's association with I-CAM that can be overcome by either 1) a virus that has a higher binding coefficient or 2) a better inhibitor. It's basic enzymology/kinetics. Go back to your Biochem. book from med. school and learn this.